Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 12, 2026 · Investor press release · Financial statements
Traws Pharma, Inc.
8
Investor press release
Jun 12, 2026
| ItemItem | Disclosure |
|---|---|
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Traws Pharma, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Traws Pharma Provides Regulatory Update on Influenza Program NEWTOWN, PA — June 12, 2026 — (GLOBENEWSWIRE) Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human…
The filing reports Items 7.01, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
Traws Pharma, Inc. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
